Story perspectives

Groundbreaking Advances in Cardiovascular Care Highlighted at 2025 Congress

9/6/2025

49 11

Summary

Story summary

The European Society of Cardiology and World Congress of Cardiology convened from August 29 to September 1, 2025, to address cardiovascular health.
AstraZeneca's Phase III trial on baxdrostat demonstrated significant blood pressure reduction in uncontrolled hypertension patients.
ESC's updated guidelines now recommend SCORE2 and SCORE2-OP for cardiovascular risk assessment in those aged 70-89.
The congress addressed women's underrepresentation in cardiovascular trials and questioned beta blockers' efficacy for heart attack patients.
Discussions emphasized AI's potential in transforming cardiovascular care and new roles for healthcare professionals.
Studies showed semaglutide and tirzepatide could lower heart failure hospitalization risk by over 40%.
Updated NICE guidelines now include pharmacists in heart failure management, stressing early medication introduction.

1 of 1

Story summary

The European Society of Cardiology and World Congress of Cardiology convened from August 29 to September 1, 2025, to address cardiovascular health.
AstraZeneca's Phase III trial on baxdrostat demonstrated significant blood pressure reduction in uncontrolled hypertension patients.
ESC's updated guidelines now recommend SCORE2 and SCORE2-OP for cardiovascular risk assessment in those aged 70-89.
The congress addressed women's underrepresentation in cardiovascular trials and questioned beta blockers' efficacy for heart attack patients.
Discussions emphasized AI's potential in transforming cardiovascular care and new roles for healthcare professionals.
Studies showed semaglutide and tirzepatide could lower heart failure hospitalization risk by over 40%.
Updated NICE guidelines now include pharmacists in heart failure management, stressing early medication introduction.